Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.

Objective: Dimethyl fumarate is a medication approved for the treatment of relapsing-remitting multiple sclerosis. The purpose of the  study was to evaluate the safety and persistence of dimethyl fumarate in  clinical practice and analyze the occurrence of lymphopenia is patients  treated with dimethyl fumarate over a period of at least 6 months.

Method: This is a retrospective longitudinal observational study carried out between August 2015 and March 2019.